Durvalumab and tremelimumab for pediatric malignancies

Trial Identifier: D419EC00001
Sponsor: AstraZeneca
NCTID:: NCT03837899
Start Date: March 2019
Primary Completion Date: February 2023
Study Completion Date: December 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
German Translation
English UK Translation
Spanish Translation
Spanish (United States) Translation
French Translation
Italian Translation
Dutch Translation

Trial Locations

Country Location
DE Jena, DE, 07747
DE Köln, DE, 50924
ES Barcelona, ES, 08035
ES Madrid, ES, 28009
FR Lille Cedex, FR, 59020
FR Marseille, FR, 13385
FR Paris Cedex 05, FR, 75248
FR Vandoeuvre les Nancy Cedex, FR, 54511
GB Leeds, GB, LS1 3EX
GB London, GB, WC1N 3JH
GB Sutton, GB, SM2 5PT
IT Genova, IT, 16100
IT Milano, IT, 20133
IT Rome, IT, 00165
IT Torino, IT, 10126
NL Utrecht, NL, 3584 CS
US, MA Boston, MA, US, 02115
US, MD Baltimore, MD, US, 21231
US, NY New Hyde Park, NY, US, 11040
US, OK Oklahoma City, OK, US, 73104
US, SC Charleston, SC, US, 29425
US, VA Washington, VA, US, 20010